DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma.
Yangyang ZhaiKun-Yan HeLiyu HuangXuyang ShangGuangxing WangGuandou YuanZe-Guang HanPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
DLK1-directed CAR-T cells specifically suppresses DLK1-positive HCC cells in vitro and in vivo. This study provides a novel transmembrane antigen DLK1 as a potential therapeutic target appropriate for CAR-T cell therapy, which may be further developed as a clinical therapeutic strategy for HCC immunotherapy.